Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.

The sleep apnea diagnostic systems market is expected to grow from US$ 4.81 billion in 2023 to US$ 9.27 billion by 2033, at a ...

There are many consequences of untreated OSA, and all of these are more likely with more-severe obstruction. Because people with OSA don't sleep well, they are at a higher risk for motor vehicle ...

With a HCPCS code and two major distribution agreements in hand, Signifier Medical Technologies is creating a path for itself and sleep stakeholders looking for an alternative to CPAP ...

Sleep apnea affects millions globally, often lurking undetected until it begins impacting overall health. While high blood ...

Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...

Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...

July 23, 2024 — Nearly 40 million adults in the U.S. have sleep apnea, and more than 30 million of them use a continuous positive airway pressure (CPAP) machine while sleeping. However ...

From sleep apnea-fighting mattresses to smart rings that play lullabies, the best sleep tech from Day 1 of CES 2025 ...

Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

Peer Support Could Help Millions With Sleep Apnea Slumber Easier, Study Says Dec. 4, 2024 — Continuous positive airway pressure, or CPAP, therapy can improve the lives of people with obstructive ...